07:48:26 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-10-23 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning INIFY 0.00 NOK
2024-05-14 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-29 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning INIFY 0.00 NOK
2023-05-16 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-30 Extra Bolagsstämma 2022
2022-08-17 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Inify Laboratories tillhandahåller cancerdiagnostik genom laboratorietjänster inom patologi. Bolaget använder ett digitalt, standardiserat arbetsflöde för svarstider och kvalitetssäkring, initialt inom prostata diagnostik. Kunderna består främst utav laboratorier och sjukhus. Inify Laboratories grundades år 2022 och har sitt huvudkontor i Stockholm, Sverige.
2023-02-23 16:19:13
From the heart of their brand-new laboratory comes this panel talk with CEO
Fredrik Palm and CTO Arto Järvinen of Inify Laboratories. Here, they discuss
progress made so far and how the Systems Engineering methodology ensures that
all components - from internal IT to equipment and logistics - fit together in
one seamless clinical workflow.

During the last quarter of 2022, Inify Laboratories moved into its brand-new
premises at Campus Solna just outside of Stockholm. The laboratory was finished
in record time and all essential milestones were reached, in terms of both
laboratory infrastructure as well as IT solutions and processes.

In this panel talk, led by Ole Eikeland, the main highlights of the quarter are
presented. Järvinen and Palm also describe how the foundation has been laid for
scalability and patient value, and provide insights into the market response so
far.

https://youtu.be/JrKmK5YARAQ

For further information, please contact CEO Fredrik Palm, fredrik.palm@inify.com
or visit https://www.inify.com/.

Inify Laboratories is currently establishing an ultramodern laboratory that will
provide cancer diagnostics within histopathology. Designed from scratch, it uses
a fully digital, standardized and AI-supported workflow to optimize quality and
shorten response times, initially within prostate cancer. The first laboratory,
located at Campus Solna Sweden, is estimated to start offering services to both
public and private healthcare providers before summer 2023.

The company originates from ContextVision, with nearly 40 years of experience
within digital imaging for medical applications and became independent through a
spin-off in February 2022. The company, based in Sweden, is listed on Euronext
Growth Oslo under the ticker INIFY.